Eric Lefkofsky is a Chicago-based entrepreneur who has made quite the name for himself in the technological world. Known initially for co-founding Groupon, Lefkofsky is now working toward making a difference in the medical field with his next co-founding startup, Tempus. Tempus is a tech firm based out of Chicago that is working to incorporate data-feeding mechanisms in order to help address the concept of cancer-related care as we know it. Lefkofsky himself got to see the cancer-care process up close when a loved one went through it and that was an inciting moment for Lefkofsky’s desire to help bring about some change to a field that is sorely in need of all the help that it can get.

Tempus was most recently appraised at a value of just north of $1 billion total. As a Chicago-based tech startup, this valuation is quite rare. Tempus employs more than 400 people at the time of this writing and it seems like the company is forecasting extreme growth in the coming months. Lefkofsky is using his industry-changing work and early fundraising endeavors as an opportunity to expand the company and focus on getting the word out regarding what they are trying to do. What IS Tempus trying to do, however?

The goal of Tempus as a company is to create a data-feeding mechanism that works hand-in-hand with medical professionals throughout clinical facilities all across the country. The goal here is for Tempus to help highlight treatment patterns for patients so that trends can develop and data collection can be pooled to help make treatment more efficient and effective in the future. Essentially, Tempus is a technological sorting system that has real-world repercussions and could potentially help bring peace and solace to people who need it during trying times.

The process of Tempus is one grounded in technological advancements and efficiency developments over the past several years and it is something that Lefkofsky is proud of. The process ranges from something as simple as digitally scanning and storing handwritten patient notes to the actual collection of molecular data from patients that are currently going through treatment.

To Read More Click Here

Leave a Reply

Your email address will not be published. Required fields are marked *